A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

Fianlimab+cemiplimab: No study drug administered in this observational study.

Study summary

This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782).

The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT03005782).

Eligibility

Primary outcome measure(s)

• Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613 — Up to 4 years

Trial sites (11)